Alignment Healthcare (ALHC) Expected to Release Earnings on Thursday

Posted by Francis Steltz on Jul 28th, 2026

Alignment Healthcare (NASDAQ:ALHC – Get Free Report) is expected to issue its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Alignment Healthcare to announce earnings of $0.13 per share and revenue of $1.3099 billion for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 5:00 PM ET.

Alignment Healthcare (NASDAQ:ALHC – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.04. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.22 billion. Alignment Healthcare had a net margin of 0.47% and a return on equity of 11.50%. The company’s revenue for the quarter was up 33.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.05) earnings per share. On average, analysts expect Alignment Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Alignment Healthcare Price Performance

Shares of NASDAQ:ALHC opened at $18.67 on Tuesday. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.58 and a current ratio of 1.58. Alignment Healthcare has a 52 week low of $11.66 and a 52 week high of $25.12. The firm has a market cap of $3.86 billion, a PE ratio of 207.44, a price-to-earnings-growth ratio of 2.62 and a beta of 1.05. The firm’s fifty day moving average is $19.62 and its 200-day moving average is $19.85.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ALHC shares. Wall Street Zen raised Alignment Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. KeyCorp reiterated an “overweight” rating on shares of Alignment Healthcare in a research report on Wednesday, June 10th. Zacks Research downgraded Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Wolfe Research started coverage on Alignment Healthcare in a research note on Friday, April 17th. They issued an “outperform” rating and a $24.00 price objective on the stock. Finally, Weiss Ratings upgraded Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.30.

Check Out Our Latest Stock Analysis on Alignment Healthcare

Insider Buying and Selling at Alignment Healthcare

In other news, insider Mark D. Kent bought 14,848 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were acquired at an average price of $13.31 per share, for a total transaction of $197,626.88. Following the completion of the acquisition, the insider directly owned 14,848 shares in the company, valued at approximately $197,626.88. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO John E. Kao sold 298,000 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $20.36, for a total transaction of $6,067,280.00. Following the sale, the chief executive officer directly owned 1,386,766 shares in the company, valued at $28,234,555.76. This trade represents a 17.69% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,039,951 shares of company stock valued at $19,976,967 over the last three months. 5.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ALHC. Wellington Management Group LLP grew its stake in Alignment Healthcare by 167.3% during the third quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock worth $193,516,000 after purchasing an additional 6,940,277 shares during the period. Invesco Ltd. lifted its stake in Alignment Healthcare by 122.3% in the second quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock valued at $58,387,000 after buying an additional 2,294,739 shares during the period. Loomis Sayles & Co. L P acquired a new position in Alignment Healthcare in the fourth quarter valued at approximately $44,162,000. Qube Research & Technologies Ltd boosted its holdings in shares of Alignment Healthcare by 269.6% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,523,986 shares of the company’s stock worth $21,336,000 after buying an additional 1,111,685 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Alignment Healthcare by 273.5% during the 3rd quarter. Bank of America Corp DE now owns 1,412,498 shares of the company’s stock worth $24,648,000 after buying an additional 1,034,273 shares in the last quarter. 86.19% of the stock is owned by institutional investors and hedge funds.

About Alignment Healthcare

(Get Free Report)

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.